Four-page summary of 2008 meeting on possibilities for intermittent PrEP research.
Trials of Intermittent Dosing of Pre-Exposure Prophylaxis (PrEP): Summary from an AVAC think tank
An Action Agenda to End AIDS: Quarterly monitoring report
The first update to An Action Agenda to End AIDS gives a status report on key actions and provides priority recommendations.
PrEP Financing in the US: Summary from an AVAC think tank
A six-page summary of an AVAC-convened think tank exploring possibilities of financing for PrEP in the United States.
An Action Agenda to End AIDS: Quarterly monitoring report
The second update to An Action Agenda to End AIDS gives a status report on key actions and provides priority recommendations.
An Action Agenda to End AIDS: Where are we in realizing the promise of beginning to end AIDS?
Issued in 2013, a year after An Action Agenda to End AIDS was first published, this document gives a status report on key actions and provides priority recommendations.
A Call to Action on Voluntary Medical Male Circumcision: Implementing a key component of combination HIV prevention
A comprehensive 2012 report from civil society about the state of voluntary medical male circumcision in Africa. Includes priority recommendations and in-depth discussion of factors influencing national scale-up efforts.
A Call to Action on Voluntary Medical Male Circumcision: Executive Summary
This is the executive summary of a 2012 joint civil society report on voluntary medical male circumcision. The document focuses on priority recommendations for action.
Influencing PEPFAR COPs: An Advocate’s Guide
A two-page resource designed for advocates working in the US and in countries receiving PEPFAR funding. It contains background information and an infographic on how PEPFAR Country Operating Plans are developed and how advocates can influence them.
Selected Trials of Long-Acting Injectables for Prevention and/or Treatment U=U of HIV
This Px Wire graphic from April-June 2014 Volume 7 No. 2 identifies selected trials of long-acting injectables in development for prevention and/or Treatment U=U of HIV.
The Global HIV Treatment U=U Gap: Existing people on ART versus people eligible under past and current WHO guidelines
This year WHO released eagerly anticipated comprehensive antiretroviral Treatment U=U (ART) guidelines addressing how to optimize ART for both Treatment U=U and prevention. The guidance recommends raising the CD4 threshold for Treatment U=U initiation to 500 CD4 cells or below — with priority given to people who are symptomatic or have CD4 cell counts at or below 350. As this graphic from AVAC Report 2013 illustrates, this shift in guidelines will increase the gap between the number of people eligible for ART worldwide and those currently receiving it.